Lotrel Articles
Lupin settles Lunesta patent litigation with Dainippon Sumitomo; Par Pharma starts shipping generic Rythmol and Lotrel
5 January 2011
US FDA clears Mylan’s generic versions of Hyzaar and Cozaar and Watson’s copy of Lotrel; Watson settles with Endo
18 October 2010
Teva returns to profit, as 4th quarter 2009 sales leap 33%
16 February 2010
Teva's 1st-qtr profit more than triples
6 May 2009
Novartis looks to single-pill BP drugs after study
15 December 2008
Teva's 2nd-qtr 2007 net sales rise 10% to $2.39B
20 August 2007
Teva resumes shipment of generic Lotrel in USA
18 June 2007
Teva gets final FDA OK for generic Lotrel
28 May 2007
Novartis' 1st-qtr 2007 profit up 11% to $2.17B on strong sales of cancer drugs and Diovan
30 April 2007
Novartis sees 16% sales jump in first three qtrs of 2006 beating consensus estimates
30 October 2006
Teva gets tentative FDA OK for generic Lotrel
17 July 2006
Novartis sees strong performance with record results in 2005
30 January 2006
Novartis nine-month net income leaps 21%
25 October 2004
American football hero Montana backs Novartis' Lotrel
8 September 2003
Profits flat at Novartis despite sales growth
21 April 2003
Analysts see threat to Novartis' Lotrel
6 January 2003
Novartis sales grow 12% in 2nd qtr
29 July 2002
Double-digit turnover growth for Novartis in 2001
11 February 2002
Double-digit turnover growth for Novartis
11 October 2001
Novartis' six-month 2001 net income jumps 10%, sales up 11%
16 August 2001
Novartis expects five new products to drive growth in 2001
15 February 2001
Novartis puts in solid 1st-half performance
21 August 2000
Novartis starts Lotrel/Innovace comparison trial
10 November 1999
Ciba Gets Positive Nine-Month Reception
23 October 1995
Sales Decline 6% At Ciba In 1995 First Half
4 September 1995
Ciba Launches Lotrel In The USA
14 August 1995
Ciba Reveals Pipeline With Broad Reach
17 April 1995
Showing 1-44 of 44 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
